IDEAS home Printed from https://ideas.repec.org/a/inm/orinte/v32y2002i6p77-90.html
   My bibliography  Save this article

How Bayer Makes Decisions to Develop New Drugs

Author

Listed:
  • Jeffrey S. Stonebraker

    (Bayer Biological Products, 4101 Research Commons, 79 T.W. Alexander Drive, Research Triangle Park, North Carolina 27709-3387)

Abstract

Drug development is time consuming, resource intensive, risky, and heavily regulated. To ensure that it makes the best drug-development decisions, Bayer Pharmaceuticals (Pharma) uses a structured process based on the principles of decision analysis to evaluate the technical feasibility and market potential of its new drugs. In July 1999, the biological products leadership committee composed of the senior managers within Bayer Biological Products (BP), a business unit of Pharma, made its newly formed strategic-planning department responsible for the commercial evaluation of a new blood-clot-busting drug. Even though Pharma's use of decision analysis began in the late 1980s, this commercial evaluation was BP's first decision analysis project. Previously, BP had analyzed a few business cases for review by Pharma. Pharma senior managers considered our recommendations relevant to their decision making. The project also institutionalized decision analysis at the business-unit level.

Suggested Citation

  • Jeffrey S. Stonebraker, 2002. "How Bayer Makes Decisions to Develop New Drugs," Interfaces, INFORMS, vol. 32(6), pages 77-90, December.
    • Handle: RePEc:inm:orinte:v:32:y:2002:i:6:p:77-90
    DOI: 10.1287/inte.32.6.77.6475
    as

    Download full text from publisher

    File URL: http://dx.doi.org/10.1287/inte.32.6.77.6475
    Download Restriction: no
    File URL: https://libkey.io/10.1287/inte.32.6.77.6475?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Samuel E. Bodily & Michael S. Allen, 1999. "A Dialogue Process for Choosing Value-Creating Strategies," Interfaces, INFORMS, vol. 29(6), pages 16-28, December.
    2. Donald L. Keefer & Samuel E. Bodily, 1983. "Three-Point Approximations for Continuous Random Variables," Management Science, INFORMS, vol. 29(5), pages 595-609, May.
    3. Donald L. Keefer, 1995. "Facilities Evaluation under Uncertainty: Pricing a Refinery," Interfaces, INFORMS, vol. 25(6), pages 57-66, December.
    4. Robert L. Schmidt, 1996. "A Stochastic Optimization Model to Improve Production Planning and R&D Resource Allocation in Biopharmaceutical Production Processes," Management Science, INFORMS, vol. 42(4), pages 603-617, April.
    5. William B. Poland, 1999. "Simple Probabilistic Evaluation of Portfolio Strategies," Interfaces, INFORMS, vol. 29(6), pages 75-83, December.
    6. Grabowski, Henry G. & Vernon, John M., 1994. "Returns to R&D on new drug introductions in the 1980s," Journal of Health Economics, Elsevier, vol. 13(4), pages 383-406.
    7. Carl S. Spetzler & Carl-Axel S. Staël Von Holstein, 1975. "Exceptional Paper--Probability Encoding in Decision Analysis," Management Science, INFORMS, vol. 22(3), pages 340-358, November.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Jeffrey S. Stonebraker, 2013. "Product-Generation Transition Decision Making for Bayer's Hemophilia Drugs: Global Capacity Expansion Under Uncertainty with Supply-Demand Imbalances," Operations Research, INFORMS, vol. 61(5), pages 1119-1133, October.
    2. Fossett, Sarah J. & Wunnava, Phanindra V., 2017. "Active Ingredients: Exploring the Key Factors Affecting the Rising Cost of Developing New Drugs," IZA Discussion Papers 10817, Institute of Labor Economics (IZA).
    3. Jeffrey S. Stonebraker & Donald L. Keefer, 2009. "OR Practice---Modeling Potential Demand for Supply-Constrained Drugs: A New Hemophilia Drug at Bayer Biological Products," Operations Research, INFORMS, vol. 57(1), pages 19-31, February.
    4. Florian Methling & Steffen A. Borden & Deepak Veeraraghavan & Insa Sommer & Johannes Ulrich Siebert & Rüdiger von Nitzsch & Mark Seidler, 2022. "Supporting Innovation in Early-Stage Pharmaceutical Development Decisions," Decision Analysis, INFORMS, vol. 19(4), pages 337-353, December.
    5. Saurabh Bansal & Yaroslav Rosokha, 2018. "Impact of Compound and Reduced Specification on Valuation of Projects with Multiple Risks," Decision Analysis, INFORMS, vol. 15(1), pages 27-46, March.
    6. Jeffrey S. Stonebraker, 2023. "Case Article—Bayer New Drug Development Decision Making," INFORMS Transactions on Education, INFORMS, vol. 23(3), pages 154-158, May.
    7. Yu, Jiun-Yu & Gittins, John, 2008. "Models and software for improving the profitability of pharmaceutical research," European Journal of Operational Research, Elsevier, vol. 189(2), pages 459-475, September.
    8. Elisa F. Long & Gilberto Montibeller & Jun Zhuang, 2022. "Health Decision Analysis: Evolution, Trends, and Emerging Topics," Decision Analysis, INFORMS, vol. 19(4), pages 255-264, December.
    9. Colvin, Matthew & Maravelias, Christos T., 2011. "R&D pipeline management: Task interdependencies and risk management," European Journal of Operational Research, Elsevier, vol. 215(3), pages 616-628, December.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Jeffrey S. Stonebraker & Donald L. Keefer, 2009. "OR Practice---Modeling Potential Demand for Supply-Constrained Drugs: A New Hemophilia Drug at Bayer Biological Products," Operations Research, INFORMS, vol. 57(1), pages 19-31, February.
    2. Donald L. Keefer & Craig W. Kirkwood & James L. Corner, 2004. "Perspective on Decision Analysis Applications, 1990–2001," Decision Analysis, INFORMS, vol. 1(1), pages 4-22, March.
    3. Jeffrey S. Stonebraker, 2013. "Product-Generation Transition Decision Making for Bayer's Hemophilia Drugs: Global Capacity Expansion Under Uncertainty with Supply-Demand Imbalances," Operations Research, INFORMS, vol. 61(5), pages 1119-1133, October.
    4. Thomas W. Keelin & Bradford W. Powley, 2011. "Quantile-Parameterized Distributions," Decision Analysis, INFORMS, vol. 8(3), pages 206-219, September.
    5. Durbach, Ian N. & Stewart, Theodor J., 2012. "A comparison of simplified value function approaches for treating uncertainty in multi-criteria decision analysis," Omega, Elsevier, vol. 40(4), pages 456-464.
    6. Moors, J.J.A. & Schuld, M.H. & Mathijssen, A.C.A., 1995. "A new method for assessing judgmental distributions," Other publications TiSEM 7ad88666-4ed3-42bf-a563-d, Tilburg University, School of Economics and Management.
    7. Moors, J.J.A. & Schuld, M.H. & Mathijssen, A.C.A., 1995. "A new method for assessing judgmental distributions," Research Memorandum FEW 708, Tilburg University, School of Economics and Management.
    8. Craig W. Kirkwood & Matthew P. Slaven & Arnold Maltz, 2005. "Improving Supply-Chain-Reconfiguration Decisions at IBM," Interfaces, INFORMS, vol. 35(6), pages 460-473, December.
    9. Werner, Christoph & Bedford, Tim & Cooke, Roger M. & Hanea, Anca M. & Morales-Nápoles, Oswaldo, 2017. "Expert judgement for dependence in probabilistic modelling: A systematic literature review and future research directions," European Journal of Operational Research, Elsevier, vol. 258(3), pages 801-819.
    10. Ali E. Abbas & David V. Budescu & Hsiu-Ting Yu & Ryan Haggerty, 2008. "A Comparison of Two Probability Encoding Methods: Fixed Probability vs. Fixed Variable Values," Decision Analysis, INFORMS, vol. 5(4), pages 190-202, December.
    11. Durbach, Ian N. & Stewart, Theodor J., 2011. "An experimental study of the effect of uncertainty representation on decision making," European Journal of Operational Research, Elsevier, vol. 214(2), pages 380-392, October.
    12. Durbach, Ian N. & Stewart, Theodor J., 2012. "Modeling uncertainty in multi-criteria decision analysis," European Journal of Operational Research, Elsevier, vol. 223(1), pages 1-14.
    13. Scherer, F.M., 2010. "Pharmaceutical Innovation," Handbook of the Economics of Innovation, in: Bronwyn H. Hall & Nathan Rosenberg (ed.), Handbook of the Economics of Innovation, edition 1, volume 1, chapter 0, pages 539-574, Elsevier.
    14. Tristan Roger & Wael Bousselmi & Patrick Roger & Marc Willinger, 2018. "The effect of price magnitude on analysts' forecasts: evidence from the lab," Working Papers hal-01954919, HAL.
    15. Tanaka, Ken'ichiro & Toda, Alexis Akira, 2015. "Discretizing Distributions with Exact Moments: Error Estimate and Convergence Analysis," University of California at San Diego, Economics Working Paper Series qt7g23r5kh, Department of Economics, UC San Diego.
    16. Robert K. Hammond & J. Eric Bickel, 2013. "Reexamining Discrete Approximations to Continuous Distributions," Decision Analysis, INFORMS, vol. 10(1), pages 6-25, March.
    17. DiMasi, Joseph A. & Hansen, Ronald W. & Grabowski, Henry G., 2003. "The price of innovation: new estimates of drug development costs," Journal of Health Economics, Elsevier, vol. 22(2), pages 151-185, March.
    18. Saurabh Bansal & Mahesh Nagarajan, 2017. "Product Portfolio Management with Production Flexibility in Agribusiness," Operations Research, INFORMS, vol. 65(4), pages 914-930, August.
    19. Simone Cerroni & Sandra Notaro & W. Douglass Shaw, 2011. "Do Monetary Incentives and Chained Questions Affect the Validity of Risk Estimates Elicited via the Exchangeability Method? An Experimental Investigation," Department of Economics Working Papers 1110, Department of Economics, University of Trento, Italia.
    20. Kleijnen, J.P.C., 1978. "Economic framework for information systems," Other publications TiSEM 45d15745-54b7-49ee-8b4e-d, Tilburg University, School of Economics and Management.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:inm:orinte:v:32:y:2002:i:6:p:77-90. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Chris Asher (email available below). General contact details of provider: https://edirc.repec.org/data/inforea.html .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.